A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)
Condition: Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB Interventions: Drug: Telacebec (Q203); Drug: Rifafour e-275 Sponsor: Qurient Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Papanicolaou (Pap) Smear | Study